Details of the Drug Combination

General Information of Drug Combination (ID: DCUI33J)

Drug Combination Name
Lixisenatide Insulin-glargine
Indication
Disease Entry Status REF
Type-2 diabetes Phase 1 [1]
Component Drugs Lixisenatide   DM0QJDC Insulin-glargine   DMR4HIW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lixisenatide
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Approved [2]
Lixisenatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [8]
------------------------------------------------------------------------------------
Indication(s) of Insulin-glargine
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [3]
Non-insulin dependent diabetes 5A11 Approved [4]
Malaria 1F40-1F45 Phase 3 [5]
Type-1 diabetes 5A10 Phase 3 [6]
Type-2 diabetes 5A11 Application submitted [7]
Insulin-glargine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Insulin (INS) TTZOPHG INS_HUMAN Modulator [9]
------------------------------------------------------------------------------------
Insulin-glargine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Insulin receptor (INSR) OTTY341H INSR_HUMAN Increases Phosphorylation [10]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Increases Phosphorylation [10]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Sanofi.
2 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
4 Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545.
5 ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 IR and IGF-1R expression affects insulin induced proliferation and DNA damage. Toxicol In Vitro. 2017 Mar;39:68-74. doi: 10.1016/j.tiv.2016.11.011. Epub 2016 Nov 22.